The European Medicines Agency (EMA) has launched a review of finasteride and dutasteride medications due to potential links with suicidal ideation and behaviors. The review aims to assess the benefit-risk balance of these drugs, which are commonly used to treat benign prostatic hyperplasia and hair loss.
The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency ( EMA ) has initiated a review of medicines containing finasteride and dutasteride due to concerns regarding potential links to suicidal ideation and behaviors. These medications, available in tablet and spray forms, are primarily used to treat benign prostatic hyperplasia (BPH). Finasteride (5 mg tablets) and dutasteride (0.
5 mg capsules) are approved for BPH, while finasteride (1 mg tablets) is also used to prevent hair loss and promote hair growth in men aged 18-41 with early-stage androgenic alopecia. Both drugs function by inhibiting the enzyme 5-alpha reductase, responsible for converting testosterone to 5-alpha-dihydrotestosterone. This inhibition slows hair loss, stimulates hair growth, and reduces prostate size. \While both drugs, particularly when taken orally, are known to carry a risk for psychiatric side effects including depression, the precise frequency of these effects remains unclear. Recently, suicidal ideation has been added as a potential side effect of unknown frequency in the product information for finasteride brands Propecia and Proscar. To mitigate these risks, existing precautionary measures include warnings for healthcare professionals to monitor patients for psychiatric symptoms and discontinue treatment if symptoms arise. Patients are also advised to seek medical advice if they experience psychiatric symptoms.\The EMA review, prompted by the French medicines agency, will comprehensively evaluate all available data to assess the impact of suicidal ideation and behaviors on the benefit-risk balance of these drugs. This evaluation will consider the specific conditions they are used to treat. During the review, marketing authorization holders will be tasked with providing comprehensive information and addressing various questions, including details on existing risk minimization measures for psychiatric disorders in each country, a thorough analysis of all relevant nonclinical and clinical trial data, pharmaco-epidemiological studies, and published literature on suicidal ideation and/or suicide following finasteride or dutasteride use. They will also be required to discuss the causal relationship between these events and treatment, as well as potential risk factors such as age, dose, route of administration, treatment duration, history of other adverse drug reactions (like persistent sexual disorders), and personal history of psychiatric disorders. The effectiveness of current risk minimization measures regarding psychiatric disorders will also be scrutinized. Ultimately, based on this comprehensive evaluation, the EMA will issue a recommendation regarding the maintenance, variation, suspension, or withdrawal of marketing authorizations for finasteride and dutasteride across the European Union
FINASTERIDE DUTASTERIDE EMA SUICIDAL IDEATION BENIGN PROSTATIC HYPERPLASIA HAIR LOSS MEDICINES REVIEW
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tata's Avinya X: A Premium Electric SUV Built on JLR's EMA PlatformTata Motors unveils the Avinya X electric SUV concept, built on Jaguar Land Rover's EMA platform, showcasing its ambition to enter the premium EV market. The concept boasts a modern design, advanced features, and a long driving range, promising a compelling alternative to established players.
Read more »
AUD/JPY Price Forecast: Pulls back from nine-day EMA near 97.50The AUD/JPY cross halts its two-day winning streak, trading around 97.00 during the Asian hours on Tuesday.
Read more »
Shiba Inu (SHIB) Dives Below 200 EMA, Raising Concerns for InvestorsShiba Inu (SHIB) is experiencing a bearish downturn, significantly underperforming the overall cryptocurrency market. The breakdown below the 200 EMA, a key technical indicator, has fueled investor pessimism. SHIB is struggling to hold above $0.00002000, with potential for further declines towards $0.00001850. The selling pressure and SHIB's inability to capitalize on market gains are raising concerns about its future prospects.
Read more »
Hair loss drug finasteride 'biggest mistake of my life'Some online sites prescribe a potentially risky hair loss drug without consistent safety checks, BBC finds.
Read more »
USD/CAD Price Forecast: Remains below 1.4400; initial support appears at nine-day EMAThe USD/CAD pair extends its gains for the second consecutive session, trading near 1.4400 during Tuesday’s Asian session.
Read more »
Lowndes County EMA director passes awayMontgomery, Alabama
Read more »